|By PR Newswire||
|August 14, 2014 05:13 PM EDT||
REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira® in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t), and area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf), with all three geometric mean ratios fully within the 90% confidence interval from 80% to 125%. Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.
"An essential global regulatory requirement is the completion of a clinical study directly comparing the originator and our biosimilar candidate establishing PK similarity," said Barbara Finck, M.D., Chief Medical Officer of Coherus. "We are pleased to have achieved robust results which we believe represents a significant reduction in development program risk."
"Adalimumab is a very complex molecule. Achieving this clinical milestone further validates Coherus' development platform and demonstrates our ability to advance biosimilars across our portfolio," said Denny Lanfear, President and Chief Executive Officer of Coherus.
About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
Coherus BioSciences Contact
SOURCE Coherus BioSciences
Oct. 25, 2016 07:45 AM EDT Reads: 1,391
Oct. 25, 2016 07:45 AM EDT Reads: 4,868
Oct. 25, 2016 06:45 AM EDT Reads: 4,815
Oct. 25, 2016 06:15 AM EDT Reads: 11,431
Oct. 25, 2016 05:45 AM EDT Reads: 3,351
Oct. 25, 2016 05:30 AM EDT Reads: 1,518
Oct. 25, 2016 05:30 AM EDT Reads: 3,374
Oct. 25, 2016 05:15 AM EDT Reads: 1,997
Oct. 25, 2016 04:45 AM EDT Reads: 1,088
Oct. 25, 2016 04:30 AM EDT Reads: 9,704
Oct. 25, 2016 04:15 AM EDT Reads: 1,011
Oct. 25, 2016 04:15 AM EDT Reads: 953
Oct. 25, 2016 04:15 AM EDT Reads: 1,740
Oct. 25, 2016 04:00 AM EDT Reads: 966
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
Oct. 25, 2016 03:45 AM EDT Reads: 1,127